An announcement from NKGen Biotech (NKGN) is now available.
NKGen Biotech, Inc. is facing a delay in submitting its quarterly financial report due to changes in its accounting and valuation firms, resulting in non-compliance with Nasdaq’s listing rules. The company has received a notice from Nasdaq but remains listed and trading, with 60 days to submit a compliance plan, extendable to 180 days. NKGen Biotech aims to file the overdue report promptly to avoid submitting a compliance plan and the risk of delisting. They’ve also issued a press release about the notice received.
For an in-depth examination of NKGN stock, go to TipRanks’ Stock Analysis page.
